"Dark Skin"-Acquired Hemophilia a After Pfizer-Biontech Covid-19 Vaccine

Gonzalez, R Salvatierra; Gutierrez-Nunez, Jose J.; Ferrer, Vanessa Fonseca; Torres, G. Torres; Cardin, Nelson Alvarez

doi:10.1016/j.chest.2021.07.1265

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search led to the identification of 14 published cases [16][17][18][19][20][21][22][23][24][25] (the flowchart reported in ►Supplementary Fig. S1 [available in the online version] describes the reviewing and the selection process).…”

Section: Resultsmentioning

confidence: 99%

“…►Table 4 identifies the 14 published cases with extracted details. [16][17][18][19][20][21][22][23][24][25] Additional details of all cases are provided in ►Supplementary Tables S4-S9 (available in the online version).…”

Section: Resultsmentioning

confidence: 99%

“…[13][14][15] Since COVID-19 vaccines were approved and rolled out in mass vaccination campaigns, a substantial number of AHA cases have been reported in temporal association with an mRNA vaccination. [16][17][18][19][20][21][22][23][24][25] Concomitantly, concerns were reported by several authors about a possible increase in the expected frequency of AHA in the population. In Switzerland, Cittone et al 22 reported a fourfold yearly increase in the number of AHA cases in 2021 compared with the expected frequency recorded in previous years.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review

Franchini

Cappello

Valdiserra

et al. 2022

Semin Thromb Hemost

View full text Add to dashboard Cite

Acquired hemophilia A (AHA), a rare but life-threatening disorder, most commonly occurs in older people and during pregnancy. During the coronavirus disease 2019 (COVID-19) vaccination campaign, an unexpected number of newly diagnosed AHA patients have been identified in clinical practice that were temporally related to COVID-19 vaccination. We present the result of a signal detection analysis aimed at exploring a possible association between COVID-19 immunization and occurrence of AHA. A disproportionality analysis on the World Health Organization (WHO) database was performed to investigate the presence of a signal of risk for AHA associated with COVID-19 vaccines. Reports of AHA associated with any COVID-19 vaccine included in the WHO database were then integrated with those available on the Food and Drug Administration Vaccine Adverse Events Reporting System and those published in the medical literature. The WHO database included 146 reports of AHA. The information component (IC) was significant for the association of AHA with all COVID-19 vaccines (IC025: 1.1) and with the vaccine product BNT162b2 (IC025: 1.6). After duplicate exclusion, 96 unique cases of AHA following COVID-19 vaccines have been reviewed. Median time to diagnosis was 18 days and 40% of cases documented the occurrence after the second dose. Overall, in 57% of the investigated cases, a preexisting condition predisposing to AHA was excluded. About 22% of cases occurred in subjects with age ≤65 years and there was no case associated with pregnancy. Mortality was 11%. Although we cannot exclude that the unexpected frequency of AHA diagnosis can be explained by a detection bias, the signal for COVID-19 vaccine-related AHA is robust and deserves further investigations.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review

Franchini

Cappello

Valdiserra

et al. 2022

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Acquired hemophilia with hemorrhagic manifestations has been reported after vaccination with adenoviral vector and BNT162b2 Pfizer–BioNTech vaccine. [ 54 , 55 ] Warm Autoimmune hemolytic anemia (AIHA) after administration of mRNA1273 vaccine [ 56 ] and hemophagocytic lymphohistiocytosis in association with inactivated SARS COV2 vaccine has also been reported. [ 57 ]…”

Section: Autoimmune Manifestations Following Covid-19 Vaccinationmentioning

confidence: 99%

Corona virus disease-19 vaccine–associated autoimmune disorders

Awan

Samreen

Salim

et al. 2022

Rheumatology and Immunology Research

View full text Add to dashboard Cite

Coronavirus disease is a highly infectious viral disease caused by severe acute respiratory syndrome virus (SARS nCoV2). It was declared a pandemic within a few months of identification of its index case. The spread of COVID-19 across the globe was rampant, overwhelming healthcare systems and crippling global economies. Since the world was caught off guard by the pandemic, vaccine programs had to be rolled out in emergency to curb its spread. Ten vaccines have been granted Emergency Use Authorization thus far. Much of the side effects we know today are post-marketing adverse effects. Most of them are mild like myalgia and injection-site reactions, but a few of them such as post-vaccination autoimmune diseases have alerted the medical community. These include vaccine-induced thrombotic thrombocytopenia, autoimmune hepatitis, myocarditis, and Graves’ disease. We attempt to summarize the diverse autoimmune phenomena reported after COVID-19 vaccination, with an aim to sensitize the medical community so that they can be better equipped in management when confronted with these diseases. This review by no means refutes the potential benefit of COVID-19 vaccination which has consolidated its place in preventing infections and substantially reducing severity and mortality.

show abstract

Acquired hemophilia A (AHA) due to anti‐SARS‐CoV‐2 vaccination: A systematic review

Amisha

Saluja

Malik

et al. 2023

eJHaem

View full text Add to dashboard Cite

Vaccination against SARS‐CoV2 has been the largest vaccination campaign over the past two decades. The aim of this study is to qualitatively assess the reported cases of acquired hemophilia A (AHA) that developed after COVID‐19 vaccination to further elaborate on incidence, presentation, treatment, and outcomes.We queried Medline (PubMed), Google Scholar, and Embase databases to find reported cases of AHA after COVID‐19 vaccines. We found 14 studies (19 cases) for this descriptive analysis. Most patients were elderly (mean age 73 years) and males (n = 12) with multiple comorbidities. All cases developed after mRNA vaccines ‐ BNT162b2 Pfizer‐BioNTech (n = 13) and mRNA‐1273 Moderna (n = 6). All except one patient were treated, with the most common therapy being a combination of steroids, immunosuppression, and rFVIII (n = 13). Two patients died due to acute respiratory distress, and gall bladder rupture with persistent bleeding, respectively. While evaluating a patient with bleeding diathesis after COVID‐19 vaccination, AHA should be kept in the differential diagnosis. Given the low incidence, we believe that the benefit of vaccination still outweighs the risk of disease acquisition.

show abstract

"Dark Skin"-Acquired Hemophilia a After Pfizer-Biontech Covid-19 Vaccine

Cited by 8 publications

References 0 publications

Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review

Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review

Corona virus disease-19 vaccine–associated autoimmune disorders

Acquired hemophilia A (AHA) due to anti‐SARS‐CoV‐2 vaccination: A systematic review

Contact Info

Product

Resources

About